Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XTR003 vs 18F-FDG PET for viable myocardium in ischemic cardiomyopathy
CTR20254963Phase 2Active
- Sponsor
- Sinotau Pharmaceutical Group
- Start
- Jan 2026
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of XTR003 in ischaemic cardiomyopathy (ICM), cardiac ischemia, sponsored by Sinotau Pharmaceutical Group. Started Jan 2026; status: active.
02
Drugs
XTR003
03
Conditions
ischaemic cardiomyopathy (ICM)cardiac ischemia
Beyond the preview
Go deeper on CTR20254963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254963.